Dechra Pharmaceuticals has said it is in a "strong position" for continued growth after reporting a half-year revenue increase of more than £10m.
The veterinary pharmaceuticals business, which is headquartered in Northwich and has significant operations in Staffordshire, posted sales of £110.7m for the six months to 31 December 2015, up from £100.9m for the same period in 2014.
Pre-tax profit also increased to £14.2m from £12.6m.
Chief executive Ian Page said he was "pleased" with the "strong performance".
"All our business units are performing well, we are in the process of launching several new products, our international expansion plans are progressing as expected and we have made two strategic acquisitions.
"We remain in a strong position to continue to grow the business and deliver returns to our shareholders."
As a result of its performance, Dechra's board has recommended an interim dividend of 5.55 pence per share, an 8.4 per cent increase on 2014.
Read more at insidermedia.com